Bedong

Researchers are evaluating the use of a postbiotic as an additional treatment for vaginal candidiasis in women. Vaginal candidiasis is a common fungal infection caused mainly by Candida albicans, leading to symptoms like vaginal itching, soreness, abnormal discharge, and discomfort during urination or sexual intercourse. The study aims to explore the effects of intravaginal administration of postbiotic compared to a placebo over four weeks, focusing on changes in vaginal microbiota and immune responses, while addressing concerns about antibiotic resistance and recurrent infections. Participants will receive either 1 gram per day of postbiotic or a placebo administered intravaginally as an adjunct treatment for four weeks. Postbiotics are inactivated probiotic components or metabolites that may provide beneficial effects without the risks associated with live probiotics. The study compares these two groups to assess the impact on vaginal microbial balance and symptoms related to candidiasis. Throughout the study, women will be monitored with vaginal sample collections to analyze microbiota profiles using next-generation sequencing at the end of the four-week treatment. Researchers will assess changes in vaginal microenvironment, gene expression, and protein concentrations. Participants are expected to commit to the full study period, with evaluations focusing on the efficacy and safety of postbiotic use as an adjunct therapy for vaginal candidiasis.